Amgen Inc., the world's biggest biotechnology company, moved closer to us approval of expanded marketing claims for its Enbrel Rheumatoid arthritis drug by winning the backing of a government advisory committee, the Los Angeles times reported.
Fda panel backs new use for Rheumatoid arthritis drug.